Stoke Therapeutics Stock Price, News & Analysis

Stoke Therapeutics (NASDAQ:STOK) reported Q2 2025 financial results and significant clinical progress. The company achieved key milestones including dosing the first patient in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and initiating a Phase 1 OSPREY study of STK-002 for ADOA treatment.

Financial highlights include a strong cash position of $355.0 million, expected to fund operations until mid-2028. Q2 2025 revenue reached $13.8 million, with a net loss of $23.5 million ($0.40 per share). The company reported positive 3-year open-label extension data for zorevunersen, showing durable seizure reductions and improved cognition in Dravet syndrome patients.

R&D expenses increased to $25.9 million in Q2 2025 from $21.1 million in Q2 2024, while G&A expenses rose to $15.3 million from $13.0 million year-over-year, reflecting increased personnel and launch preparation costs.

Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine and protein expression restoration, has scheduled a webcast and conference call for August 12, 2025, at 4:30 p.m. ET. The event will cover the company's second quarter 2025 business and financial updates.

The company's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome. Research analysts can register for Q&A participation, while other participants can access the listen-only webcast through the company's investor relations website. The webcast recording will be available for at least 90 days after the event.

Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Interim CEO Ian F. Smith will deliver a presentation on Wednesday, August 13, 2025, at 11:30 a.m. ET.

The company, which is developing zorevunersen as a potential first-in-class treatment for Dravet syndrome, will make the presentation available via live webcast on their investor relations website, with an archived replay accessible afterward.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced inducement grants to three new employees, including newly-appointed Chief People Officer Sara Den Besten. The company granted Ms. Den Besten options to purchase 260,000 shares of common stock at $11.75 per share, while two other employees received options to purchase an aggregate of 130,000 shares.

All options have a 10-year term and will vest over a 4-year period, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The grants were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Stoke Therapeutics (NASDAQ: STOK), a biotechnology company focused on RNA medicine and protein expression restoration, has granted inducement stock options to two new employees. The grants, effective June 16, 2025, total 37,200 shares with an exercise price of $11.70 per share, matching the company's closing price on that date. The options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over 36 months. These 10-year options were granted under the 2023 Inducement Plan as material inducement for employment. Stoke's lead product, zorevunersen, is being developed as a potential first-in-class treatment for Dravet syndrome.

Stoke Therapeutics (NASDAQ: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced that Interim CEO Ian F. Smith will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 1:25 p.m. ET. The company's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome. A live webcast and replay of the presentation will be accessible through Stoke's investor relations website.

Stoke Therapeutics (NASDAQ: STOK) reported strong Q1 2025 financial results and significant progress in developing zorevunersen for Dravet syndrome. The company achieved regulatory alignment for its Phase 3 EMPEROR study, expected to start in Q2 2025. A notable collaboration with Biogen was established, bringing in $165 million upfront with potential milestone payments of up to $385 million. Stoke maintains exclusive rights in North America while Biogen gets rest-of-world commercialization rights. Q1 2025 financials showed net income of $112.9 million ($1.90 per diluted share), compared to a loss in 2024. The company's strong cash position of $380.3 million is expected to fund operations through mid-2028, supporting Phase 3 data readout and launch preparations.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's Interim Chief Executive Officer Ian F. Smith will deliver a presentation on Tuesday, April 8, 2025, at 8:45 a.m. ET. Stoke's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome.

Investors and interested parties can access the live webcast and archived replay of the presentation through Stoke's website investor section at https://investor.stoketherapeutics.com/.

Stoke Therapeutics (NASDAQ: STOK) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its Dravet syndrome treatment program. The company's lead investigational medicine, zorevunersen, is advancing to Phase 3 EMPEROR study in Q2 2025.

Key financial highlights include:

• Cash position of $246.7 million as of December 31, 2024
• Full-year 2024 revenue of $36.6 million, up from $8.8 million in 2023
• Net loss of $89.0 million ($1.65 per share) in 2024, improved from $104.7 million in 2023

Notable developments include a new collaboration with Biogen, FDA Breakthrough Therapy Designation for zorevunersen, and positive clinical data presented at AES 2024. The company expects its current cash position, combined with the $165 million Biogen collaboration upfront payment, to fund operations until mid-2028.